SCI Pharmtech Stock

SCI Pharmtech Liabilities

The The Liabilities of SCI Pharmtech (4119.TW) as of Aug 20, 2026 is 1.49 B TWD. In the previous year, The Liabilities was 1.72 B TWD — a change of -13.43% (lower).

Liabilities

1.49 BTWD

YoY

-13.43%

Last updated:

In 2026, SCI Pharmtech's total liabilities amounted to 1.49 B TWD, a -13.43% difference from the 1.72 B TWD total liabilities in the previous year.

Access this data via the Eulerpool API

SCI Pharmtech Stock analysis

What does SCI Pharmtech do? SCI Pharmtech Inc is a leading company in the pharmaceutical industry based in Zhejiang, China. The company was founded in 2003 and has since grown continuously. Today, the company employs over 100 employees and has become a key player in the global supply chain of pharmaceutical raw materials and intermediates. SCI Pharmtech Inc's business model is based on the development and production of high-quality pharmaceutical intermediates and active pharmaceutical ingredients, as well as the manufacturing of custom chemicals. The company specializes in the production and distribution process, offering its customers a comprehensive range of products that meet the highest quality and safety standards. SCI Pharmtech Inc is divided into various divisions, each specializing in specific product categories. The main divisions are API (Active Pharmaceutical Ingredients), intermediates, and custom synthesis. The API division produces active pharmaceutical ingredients for the pharmaceutical industry, which serve as the basis for drug manufacturing. The intermediates division offers pharmaceutical intermediates used in the synthesis of active pharmaceutical ingredients. The custom synthesis division provides tailored synthesis processes for customers in need of specific chemicals or intermediates. SCI Pharmtech Inc's product portfolio includes Acetamidomalonate, Carbamazepine, and Codergocrine Mesylate, among others. The company also offers custom synthesis services, involving complex chemical syntheses and innovative technologies. SCI Pharmtech Inc places great emphasis on quality and safety. The company operates according to international standards, including GMP (Good Manufacturing Practice), ISO (International Standards Organization), and CE (Conformité Européenne). SCI Pharmtech Inc's products undergo stringent quality controls to ensure compliance with the strict regulations of global pharmaceutical regulatory authorities. Another important concern of SCI Pharmtech Inc is sustainability. The company has developed a sustainable business strategy aimed at minimizing its environmental impact and conserving resources. This includes implementing efficient production processes, reducing energy consumption and CO2 emissions, as well as promoting environmental awareness among employees and customers. Overall, SCI Pharmtech Inc is a dynamic and innovative company specializing in the production of pharmaceutical intermediates and active pharmaceutical ingredients. The company takes pride in offering high-quality products that meet the highest quality and safety standards. Through its sustainable business strategy and adherence to international standards, SCI Pharmtech Inc has achieved an excellent reputation in the pharmaceutical industry and strengthened its presence in the global market. SCI Pharmtech is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing SCI Pharmtech's Liabilities

SCI Pharmtech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating SCI Pharmtech's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing SCI Pharmtech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

SCI Pharmtech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in SCI Pharmtech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about SCI Pharmtech stock

The Liabilities of SCI Pharmtech is 1.49 B TWD in 2026.

The Liabilities of SCI Pharmtech changed from 1.72 B TWD to 1.49 B TWD, representing a -13.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities SCI Pharmtech since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's SCI Pharmtech historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — SCI Pharmtech

All Key Metrics — SCI Pharmtech